Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis

被引:26
|
作者
Strand, Vibeke [1 ]
Tundia, Namita [2 ]
Song, Yan [3 ]
Macaulay, Dendy [3 ]
Fuldeore, Mahesh [2 ]
机构
[1] Stanford Univ, Sch Med, Div Immunol Rheumatol, Palo Alto, CA 94304 USA
[2] AbbVie, N Chicago, IL USA
[3] Anal Grp, Boston, MA USA
来源
关键词
METHOTREXATE THERAPY; CONTROLLED-TRIAL; DOUBLE-BLIND; TOCILIZUMAB; COMBINATION; ETANERCEPT; PREVALENCE; INFLIXIMAB; ADALIMUMAB; INHIBITOR;
D O I
10.18553/jmcp.2018.24.4.344
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BACKGROUND: Targeted immunomodulators (TIMs), including biologic disease-modifying antirheumatic drugs (DMARDs) and JAK/STAT inhibitors, are effective therapies for rheumatoid arthritis (RA), but some patients fail to respond or lose response over time. This study estimated the real-world prevalence of RA patients with inadequate responses to an initial TIM (nonresponders) in the United States and assessed their direct and indirect economic burden compared with treatment responders. METHODS: Administrative claims data (January 1999-March 2014) from a large private-insurer database were used, which included work-loss data from a subset of reporting companies. Eligible patients (classified as responders and nonresponders) had >= 1 claim for a TIM approved for the treatment of RA and >= 2 RA diagnoses in the claims history, with continuous pharmaceutical and medical benefit eligibility for 6 months before (baseline) and 12 months after (study period) the date of the first TIM claim (index date). All-cause and RA-related health care resource use (HCRU) and costs, work loss, and indirect costs during the study period were compared for responders versus nonresponders. Multivariable regression was used to adjust for baseline covariates. Sensitivity analyses of HCRU and direct costs were conducted for patients with index dates before and after 2008 to account for different approval dates of TIMs. RESULTS: Of 7,540 eligible patients with RA, 2,527 (34%) were classified as responders, and 5,013 (66%) were classified as nonresponders; 407 and 723 had work-loss data, respectively. After adjusting for baseline covariates, nonresponders had significantly higher HCRU, including inpatient admissions (incidence rate ratio [IRR] = 1.94), outpatient visits (IRR = 1.19), emergency department visits (IRR = 1.53), and number of prescription fills (IRR = 1.09; all, P < 0.001). Nonresponders also had significantly higher adjusted all-cause ($12,868 vs. $9,621, respectively) and RA-related ($5,740 vs. $4,495; both, P < 0.001) medical costs compared with responders. In addition, nonresponders reported significantly more days of work lost compared with responders (22.1 vs. 16.7 days, respectively; IRR = 1.21; P = 0.007) and higher indirect costs ($3,548 vs. $2,890; P = 0.002). Sensitivity analyses of HCRU and direct costs by index date (before and after 2008) were consistent with the full sample. CONCLUSIONS: A large portion of patients with RA had inadequate responses to their initial TIM therapy with significantly higher economic burden, including higher HCRU, medical costs, and indirect costs due to work loss, compared with TIM therapy responders. Copyright (C) 2018, Academy of Managed Care Pharmacy. All rights reserved.
引用
收藏
页码:344 / 352
页数:9
相关论文
共 50 条
  • [41] The economic burden of fibromyalgia: comparative analysis with rheumatoid arthritis
    Silverman, Stuart
    Dukes, Ellen M.
    Johnston, Stephen S.
    Brandenburg, Nancy A.
    Sadosky, Alesia
    Huse, Dan M.
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (04) : 829 - 840
  • [42] Quantifying the economic burden of productivity loss in rheumatoid arthritis
    Filipovic, Ivana
    Walker, David
    Forster, Fiona
    Curry, Alistair S.
    RHEUMATOLOGY, 2011, 50 (06) : 1083 - 1090
  • [43] A Clinical Update and Global Economic Burden of Rheumatoid Arthritis
    Fazal, Syed Ali
    Khan, Mohammad
    Nishi, Shamima E.
    Alam, Fahmida
    Zarin, Nowshin
    Bari, Mohammad T.
    Ashraf, Ghulam Md.
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2018, 18 (02) : 98 - 109
  • [44] The Economic Burden of Biological Drugs in Rheumatoid Arthritis Treatment
    Grega, Dominik
    Kolar, Jozef
    VALUE IN HEALTH REGIONAL ISSUES, 2024, 40 : 13 - 18
  • [45] Sustainability of Response Between Upadacitinib and Adalimumab Among Patients with Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate
    Nash, Peter
    Kavanaugh, Arthur
    Buch, Maya
    Combe, Bernard
    Bessette, Louis
    Song, In-Ho
    Song, Yanna
    Suboticki, Jessica
    Fleischmann, Roy
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [46] SUSTAINABILITY OF RESPONSE BETWEEN UPADACITINIB AND ADALIMUMAB AMONG PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO METHOTREXATE
    Nash, Peter
    Kavanaugh, Arthur
    Buch, Maya
    Combe, Bernard
    Bessette, Louis
    Song, In-Ho
    Song, Yanna
    Suboticki, Jessica
    Fleischmann, Roy
    INTERNAL MEDICINE JOURNAL, 2021, 51 : 46 - 47
  • [47] SUSTAINABILITY OF RESPONSE BETWEEN UPADACITINIB AND ADALIMUMAB AMONG PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO METHOTREXATE
    Nash, P.
    Kavanaugh, A.
    Buch, M. H.
    Combe, B.
    Bessette, L.
    Song, I. H.
    Song, Y.
    Suboticki, J.
    Fleischmann, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 643 - 644
  • [48] Prediction of Response to Targeted Treatment in Rheumatoid Arthritis
    Wijbrandts, C. A.
    Tak, P. P.
    MAYO CLINIC PROCEEDINGS, 2017, 92 (07) : 1129 - 1143
  • [49] Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World US Data
    Gharaibeh, Mahdi
    Bonafede, Machaon
    McMorrow, Donna
    Hernandez, Ervant J. Maksabedian
    Stolshek, Bradley S.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (08): : 1039 - +
  • [50] ECONOMIC BURDEN OF RHEUMATOID ARTHRITIS IN ITALY: POSSIBLE CONSEQUENCES ON EARLY RAPIDLY PROGRESSING PATIENTS
    Mennini, F. S.
    Marcellusi, A.
    Gitto, L.
    Iannone, F.
    VALUE IN HEALTH, 2016, 19 (07) : A536 - A536